Cancers (Jun 2023)

Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study

  • Youngji Kwak,
  • Sung Yoon Jang,
  • Joon Young Choi,
  • Hyunjun Lee,
  • Dong Seung Shin,
  • Yeon Hee Park,
  • Ji-Yeon Kim,
  • Jin-Seok Ahn,
  • Byung Joo Chae,
  • Jonghan Yu,
  • Jeong Eon Lee,
  • Seok Won Kim,
  • Seok Jin Nam,
  • Jai Min Ryu

DOI
https://doi.org/10.3390/cancers15133435
Journal volume & issue
Vol. 15, no. 13
p. 3435

Abstract

Read online

Background: Although estrogen receptor (ER) expression levels affect the prognosis of breast cancer, studies about progesterone receptor (PR) expression levels are insufficient, especially in young breast cancer (YBC). The purpose of this study was to compare clinical characteristics and prognosis according to PR expression levels in invasive breast cancer patients. Methods: A prospective cohort study was conducted to identify YBC patients with invasive carcinoma diagnosed at an age of less than 40 years old between 2013 and 2018. Clinicopathologic features and prognosis of ER-positive and human epidermal growth factor receptor 2 (HER2)-negative patients were investigated. Patients were stratified into strong PR (PR-positive cell proportion > 10%), low PR (PR-positive cell proportion = 1~10%), and PR-negative (PR-positive cell proportion p = 0.0033, p = 0007). Low PR group had an even higher risk of distant metastasis than PR-negative patients. Low PR patients and PR-negative had significantly lower overall survival (OS) rates than strong PR. Conclusion: Low PR might be a prognostic factor of ER-positive/HER2-negative in YBC.

Keywords